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Abstract
There are challenges regarding increased global rates of microbial resistance and the emergence of new mechanisms that
result in microorganisms becoming resistant to antimicrobial drugs. Fosfomycin is a broad-spectrum bactericidal antibiotic
effective against Gram-negative and certain Gram-positive bacteria, such as Staphylococci, that interfere with cell wall
synthesis. During the last 40 years, fosfomycin has been evaluated in a wide range of applications and fields. Although
numerous studies have been done in this area, there remains limited information regarding the prevalence of resistance.
Therefore, in this review, we focus on the available data concerning the mechanisms and increasing resistance regarding
fosfomycin.
INTRODUCTION
The alarming increase in antibiotic resistance rates reported
among various pathogens has resulted in the employment of
alternative treatment policies. Since the availability of novel
antimicrobial drugs is rather limited, the reassessment of
older antibiotic agents appears to be an interesting option
[1, 2]. Fosfomycin (also known as phosphomycin), a bacte-
ricidal phosphoenolpyruvate (PEP) analogue previously
used as oral treatment for uncomplicated urinary tract infec-
tions (UTIs), has recently interested clinicians all around
the world [3]. Mostly, the reported advanced resistance
against pathogens suggests that fosfomycin can serve as an
appropriate treatment option in patients with highly resis-
tant microbial infections. Although many researches have
been carried out on fosfomycin’s characterization, there
remains no centralized information regarding the current
level of resistance. In this review, referring to the key data




The history of fosfomycin began in 1969, when it was first
isolated from Streptomyces fradiae in soil samples using
broth cultures [4, 5]. It was subsequently extracted from
Streptomyces virichromogens and Streptomyces wedmorensis,
by American and Spanish researchers, independently [in a
joint effort of Merck and Co. and Spain’s Compañía Espa-
ñola de Penicilina y Antibióticos (CEPA)] [4, 6]. However,
this antibiotic was soon developed by chemical synthesis
and its medical use began in 1971 [7]. Fosfomycin was
approved by the USA in 1997 and commonly used for
uncomplicated UTI caused by susceptible organisms [8–10].
Phosphonic acid derivatives, and particularly fosfomycin,
attracted many researchers: its unique mechanism and
structure are at the core of its clinical properties and partic-
ular actions [11–13]. Despite fosfomycin’s efficacy and
favourable characteristics some problems arose, including
the poor bioavailability of the drug when administered by
the oral route, the variation in activity in different culture
media and, consequently, difficulties in determination of its
antimicrobial activity and the rapid emergence of resistant
strains [14, 15].
Fosfomycin has the smallest molecular mass among existing
antibiotics (138Da), which confirms its wide ability to dif-
fuse. It is a strongly polar molecule, soluble in water and its
pharmacological properties are unchanged under normal
storage conditions for 2–3 years. Fosfomycin is unstable in
an acidic environment and thus has poor oral bioavailability
in the disodium salt form, which is used for the parenteral
route [8]. However, fosfomycin-trometamol is a hydro-
soluble product, facilitating use of the oral route of adminis-
tration [16].
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Fosfomycin is associated with phosphonic antibiotics, of
which there are three types administered by the parenteral
route: fosfomycin, fosmidomycin and alafosfalin. Primarily,
fosfomycin disodium is administered parenterally to
patients with serious infections, such as meningitis [9].
Recently it has been produced in an oral form, fosfomycin-
trometamol, a monobasic hydro-soluble fosfomycin salt
administered specifically in UTIs. Fosfomycin-trometamol
is accessible in the form of a white crystalline powder. With
the exception of fosfomycin-trometamol salt, the available
data on other related products is limited [8]. In certain
European countries, fosfomycin disodium is sometimes
used to treat patients with soft tissue infections and sepsis
[17].
In many countries, including Spain, France, Austria, Brazil,
Germany, Japan and South Africa, fosfomycin has been
used effectively via the intravenous route for nearly four
decades [17]. In Europe, the utilization of intravenous fosfo-
mycin disodium for patients with sepsis, soft tissue infec-
tions and deep-seated infections has become well
established over the last 18 years. Conversely, the United
States Food and Drug Administration (FDA) has affirmed
the use of oral fosfomycin-tromethamine alone for the treat-
ment of uncomplicated lower UTIs caused by Escherichia
coli or Enterococcus faecalis, due to limited clinical analysis
[17]. Unfavourable results, predominantly in regard to the
treatment of acute gonococcal urethritis, have led to a lim-
ited acceptance of fosfomycin in the United States. How-
ever, 40 years of clinical experience documents that
intravenous fosfomycin is effective and well tolerated in a
variety of patient populations. Consequently, fosfomycin
could be an appropriate choice in the therapy of deep-seated
and severe infections [18]
Chemical structure
Fosfomycin ([(2R, 3S)-3-methyloxiran-2-yl] phosphonic
acid), is an exclusive antibiotic whose chemical structure is
unlike that of other known antibacterial agents [19]. Being
small and hydrophilic, it shows insignificant serum protein-
binding tendency [20]. The molecular structure of
fosfomycin varies based on the available drug formulations.
Generally, it is accessible in two oral formulations, fosfomy-
cin-trometamol (or fosfomycin-tromethamine) (C3H7O4P.
C4H11NO3) (Fig. 1a) and fosfomycin-calcium
(C3H5CaO4P) (Fig. 1b). The intravenous formulation of




As antibiotic selection options gradually decrease, fosfomy-
cin assumes increasing importance due to its efficacy against
multidrug-resistant pathogens [22, 23]. First is its oral bio-
availability that allows it to actively reach tissues and main-
tain high blood levels, and and the achievement of
therapeutic results before resistance occurs. Fosfomycin-tro-
metamol appears to fit this description [24]. In fact, fosfo-
mycin-trometamol was shown to have, in comparison to
other phosphonic acid derivatives, (1) a similar safety pro-
file [25]; (2) a similar profile of bacteriological activity
Fig. 1. (a) Molecular structure of fosfomycin-trometamol. (b) Molecular structure of fosfomycin-calcium. (c) Molecular structure of fos-
fomycin-disodium.
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comparable to other agents [26, 27]; and (3) enhanceded
oral bioavailability [28, 29].
Fosfomycin is rapidly absorbed by the oral route, and its
bioavailability is almost 40% for fosfomycin-trometamol vs.
12% for the fosfomycin-calcium salt. Fosfomycin has good
tissue dissemination in different sites such as the lungs,
serum, prostate, kidneys, liver, cerebrospinal fluid, pus,
bladder wall, inflammatory tissue, heart valves and bone
[30, 31]. It is excreted in the urine unchanged, reaching
high concentrations over a period of time [9]. About 30–
60% of fosfomycin-trometamol is excreted unchanged via
the urine, versus 9–18% for the calcium salt [28]. Fosfomy-
cin has a renal exclusion of 95%, with no tubular secretion,
and a relatively long elimination half-life, ranging 4–10 h
[32]. Due to the low rate of fosfomycin recovery in patients
with chronic renal failure, its half-life is enhanced signifi-
cantly (up to 50 h) [32]. The serum concentration of fosfo-
mycin is higher when administered prior to the intake of
food, pharmacokinetic parameters showing a significantly
decreased absorption of the compound. Fifty-one per cent
of the dose consumed is excreted in the urine over 24 h [33,
34]. Urinary fosfomycin concentrations are high and may
exceed 2000mg l 1 after a single dose, they remain high for
a long time (usually more than 24 h), resulting in a chal-
lenge regarding common therapies for UTIs [8].
When considering fosfomycin MIC50 and MIC90 concentra-
tions against pathogenic bacteria, it is clearly understood
that this agent is especially active against the most common
pathogens causing UTIs, including E. coli, Enterobacter spp.,
Citrobacter spp. and Proteus mirabilis. However, its suscep-
tibility rate can vary among these pathogens. However, on
the basis of pharmacokinetic behaviour, the bioavailability
of fosfomycin is far better than that of its calcium salt [24].
After oral administration of the calcium or trometamol salt
(50mg kg 1), the peak serum level of the former was almost
30mg l 1 while that of the latter is near 5mg l 1. Almost 10
h after administration of fosfomycin-trometamol, the serum
level of fosfomycin was 3–5mg l 1 [35]. These results show
an extended period of time in the urine – an unexpected
finding – since the half-life of fosfomycin-trometamol is
about 3–4 h, which has been attributed to the enterohepatic
recirculation of the drug as recognized by a secondary peak
in the serum level curve [16, 36]. These observations in the
preliminary phase of fosfomycin-trometamol studies led to
the conclusion that fosfomycin-trometamol is a very safe
drug, as well as the recognition that it delivers high bacteri-
cidal concentrations of the drug to the urine for at least 36–
48 h. Therefore, researchers have now reconsidered this
drug. Indeed, the high urinary levels facilitate long-lasting
bactericidal activity and inhibit the presence of resistant
strains. These characteristics are required for a drug specifi-
cally indicated for ‘single-dose treatment’ of lower uncom-
plicated UTIs [37, 38]. The ideal drug profile for single-dose
therapy of lower UTIs includes the following: (1) Very low
toxicity; (2) bactericidal activity against most uropathogens;
(3) high drug concentrations in the urine over an extended
period; (4) no emergence of resistance; and (5) no cross-
Fig. 2. Mechanism of action of fosfomycin.
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resistance with other antibiotics. These parameters are
achieved by fosfomycin-trometamol, providing the back-
ground for the clinical acceptance of fosfomycin-
trometamol in lower uncomplicated UTIs [1, 39, 40].
The pharmacodynamic index that best links drug exposure
to antimicrobial efficacy is significant for understanding the
optimal use of fosfomycin, in terms of bacterial killing and/
or preventing the development of resistant populations.
Historically, fosfomycin has been considered as an agent
with a time-dependent antimicrobial effect [20]. In a study
by Docobo-Perez, dose fractionation research was con-
ducted with two ESBL-producing strains with a fosfomycin
MIC of 1mg l 1. In both cases, the administration of fosfo-
mycin resulted in the same level and extent of bacterial kill-
ing, irrespective of the administration schedule [20]. In
another study, the pharmacokinetics of fosfomycin were
surveyed in mice infected with Gram-negative bacterial
pathogens (E. coli, K. pneumoniae and P. aeruginosa) after
subcutaneous administration of 3.125, 12.5, 50, 200, 400
and 800mg kg 1. The half-life ranged from 0.51 to 1.1 h,
the area under the concentration–time curve (AUC0-¥)
ranged from 1.4 to 87mgh l 1, and maximum concentra-
tions ranged from 0.6 to 42.4mg l 1. Dose fractionation
demonstrated the AUC/MIC ratio to be the PK/PD index,
most closely linked to efficacy (R2=0.70). Net stasis and bac-
tericidal activity were detected against all isolates [41].
These findings should prove useful in the design of clinical
dosing regimens for fosfomycin in serious infections due to
Enterobacteriaceae and Pseudomonas.
MODE OF ACTION
Fosfomycin has a bactericidal action that inhibits the bio-
synthesis of peptidoglycan in both Gram-positive and -
negative bacteria during the first step, leading to bacterial
cell lysis and death [13]. Fosfomycin acts as a phospho-
enolpyruvate (PEP) analogue and binds to MurA (UDP-
GlcNAc enolpyruvyl transferase), an essential enzyme for
peptidoglycan biosynthesis [42], catalysing the transfer of
the enolpyruvyl moiety of PEP to the 3¢-hydroxyl group
of UDP-N-acetylglucosamine (UNAG) [43]. Thereby, it
prevents the formation of N-acetylmuramic acid from N-
acetyl-glucosamine and phosphoenolpyruvate, finally
resulting in bacterial cell lysis and death (Fig. 2) [44, 45].
In fact, the effect of fosfomycin on the active site of
MurA inhibits this enzyme by a covalent thioether bond
formation with a key residue in the active site, Cys115
[44]. Fosfomycin uses the glycerol-3-phosphate transport
(GlpT) and hexose phosphate uptake transport (UhpT)
systems (providing an alternative for GlpT system for its
influx into cells) as methods of entry in almost all suscep-
tible bacteria to achieve membrane lysis of the target
pathogen (Fig. 2) [45–47].
International committees for susceptibility
breakpoints
The only approved minimum inhibitory concentration
(MICs) method for testing is agar dilution, using agar media
supplemented with 25 µgml 1 glucose-6-phosphate. Broth
dilution MIC testing should not be performed. Breakpoints
to define resistance for licensed use differ: 256mg l 1
according to the Clinical and Laboratory Standards Institute
(CLSI), >128mg l 1 according to the British Society for
Antimicrobial Chemotherapy and >32mg l 1 according to
the Committee on Antibiograms of the French Society of
Microbiology. The European Committee on Antimicrobial
Susceptibility Testing (EUCAST) has definedthe clinical
MIC breakpoint for fosfomycin and enterobacteriaceae as
R>32mg l 1 [48, 49]. Specifically, according to the CLSI,
MIC values should be interpreted on the basis of the follow-
ing criteria: MIC64mgml 1: susceptible (S); MIC 128mg
ml 1: intermediate (I); MIC256mgml 1: resistant (R)
[21].
Activity against Gram-negative bacteria
Studies have revealed a stable susceptibility over time
against common uropathogenic Gram-negative bacteria,
including E. coli, Pseudomonas aeruginosa and Stenotropho-
monas maltophilia [50, 51]. Although P. aeruginosa and
Stenotrophomonas maltophilia showed moderate suscepti-
bility, A. baumannii isolates were intrinsically resistant to
fosfomycin monotherapy [44, 52]. However, a combination
of fosfomycin with other antibiotics (cefepime, aztreonam
or meropenem) was effective in an in vitro study involving
P. aeruginosa clinical isolates [53]. Fosfomycin is not active
against anaerobic bacteria such as Bacteroides spp., but it is
active against Peptococcus and Peptostreptococcus spp. [54].
Activity against Gram-positive bacteria
Fosfomycin is also very effective against Gram-positive
cocci, including Staphylococcus aureus, Enterococcus faeca-
lis, Staphylococcus epidermidis, Enterococcus faecium and
Streptococcus pneumoniae [6]. It has in vitro effective activ-
ity against S. aureus (MIC50, 8mg l
 1; MIC90, 16mg l
 1)
[55]. Listeria monocytogenes is resistant to fosfomycin,
whereas other Listeria species (e.g. Listeria ivanovii) may be
susceptible [56]. However, intrinsically resistant bacteria to
fosfomycin include Staphylococcus capitis, Staphylococcus
saprophyticus andMycobacterium tuberculosis [54].
Previous studies have thus indicated that fosfomycin is a
successful treatment option for infections caused by multi-
drug-resistant (MDR) Gram-positive and -negative patho-
gens [39, 57]. However, fosfomycin resistance needs to be
continuously surveyed and its molecular characteristics
have to be understood to prevent the future emergence of
and increase in MDR bacterial strains with fosfomycin resis-
tance in the clinical setting.
MECHANISMS OF RESISTANCE
Bacterial resistance to fosfomycin can be either chromo-
somal or plasmid mediated. Most chromosomally resistant
mutants that do not easily transfer to other organisms have
an impaired uptake system [58], whereas plasmid-resistant
mutants are generally known to be multi-resistant and can
transfer their resistance to other organisms through
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conjugation or transformation [58, 59]. Bacterial resistance
to fosfomycin occurs via three mechanisms, two of which
are based on chromosomal genes and the third on plasmids
[60].
Reduced permeability to fosfomycin
The main mechanism for acquisition of fosfomycin resis-
tance is an inactivation in phosphonate transport or uptake
pathways [61]. In E. coli, two main nutrient transport sys-
tems, the glycerol-3-phosphate transporter (GlpT) and the
glucose-6-phosphatetransporter (UhpT), are responsible for
fosfomycin uptake [62]. Expression of these genes (glpT,
uhpT) requires the presence of cAMP levels that can be low-
ered by mutations in the ptsI or cyaA genes (which will also
affect catabolism in a variety of carbohydrates), and for the
uhpT gene, high-level expression requires the regulatory
gene uhpA [62–64]. Mutations in each regulatory gene of
those pathways decrease antibiotic uptake, conferring differ-
ent levels of fosfomycin resistance [62, 65].
Strains defective in fosfomycin uptake are not able to grow
using only a carbon source, glycerol-3-P in GlpT-deficient
strains or glucose-6-P (and other hexose phosphates) in
Uhp-deficient strains [44]. However, in P. aeruginosa fosfo-
mycin can only enter cells via GlpT. As a result, glpT is the
key target gene whose inactivation confers antibiotic resis-
tance in E. coli and P. aeruginosa [44, 66]. In L. monocyto-
genes, due to lack of antibiotic transport the bacterium is
intrinsically resistant to fosfomycin. Nevertheless, the in
vivo virulence factor Hpt, a glucose-6-P permease, mediates
the uptake of fosfomycin, conferring antibiotic susceptibility
during infection [44]. The in vitro researches on interaction
between GlpT and fosfomycin in proteoliposomes show
that fosfomycin competes for the substrate-binding site of
the permease and is transported by the protein. The interac-
tion of GlpR (the GlpT repressor) with glycerol-3-P reduces
its affinity for the glpT operator and activates GlpT synthesis
[44, 67, 68].
Inactivation of the cAMP receptor protein (CRP) impairs
the expression of both transporter systems and increases
resistance to fosfomycin [69]. The GlpTQ operon contains
several cAMP–CRP binding sites in a DNA stretch, nega-
tively and positively controlled by GlpR and cAMP–CRP,
respectively [70].
Modification of the antibiotic target MurA
One of the most common mechanisms resulting in Fosfo-
mycin resistance is modification of the antibiotic MurA
(UDP-N-acetylglucosamine enolpyruvyl transferase) target,
which inactivates the enzyme by irreversibly binding to the
protein. In E. coli, mutation of the fosfomycin-binding site
inMurA, Cys115, results in resistance to this antibiotic [71].
MurA shows enzymatic activity that is susceptible to block-
age by fosfomycin in a dose-dependent manner. In certain
pathogenic bacteria, such as Mycobacterium tuberculosis,
Chlamydia trachomatis, Vibrio fischeri and Borrelia burg-
dorferi, the Asp residue is present in the catalytic site of
MurA proteins. Mutations in the Asp, Cys115 to Glu allow
MurA to act as intrinsic resistance to fosfomycin [54, 72–
74]. However, mutations in the murA gene seem to be rare
in clinical isolates. Mutations in the MurA sequence of
E. coli in the clinical isolates Leu370 to Ile and Asp369 to
Asn have recently been reported to represent the onset of in
vivo Fosfomycin resistance [75]. According to another
study, the identification of a salvage pathway producing
peptidoglycan in Pseudomonas putida from UDP-MurNAc
is catalysed by MurA, which is the first peptidoglycan pre-
cursor [76].
Antibiotic modification
Several enzymes that inactivate fosfomycin by covalent
modification cleave the carbon–oxygen bond of the epoxide
moiety, including the phosphonate kinases FomA and
FomB and the thiol transferases, glutathione-fosfomycin
(FosA), L-cysteine-fosfomycin (FosB), ATP-fosfomycin
(FosC) and water-fosfomycin (FosX), which catalyse the
addition of glutathione or cysteine to fosfomycin [58, 77–
80]. The loci of fomA and fomB have been identified in
those strains with high-level resistance to fosfomycin and
which encode polypeptides with low-level sequence identity
to eukaryotic protein kinases [78]. Biochemical studies with
recombinant enzymes show that FomA and FomB catalyse
the phosphorylation of fosfomycin to fosfomycin mono-
phosphate, and subsequently to fosfomycin diphosphate
[61].
According to biochemical and structural studies, FosA types
are metaloenzymes that catalyse the nucleophilic addition of
the tri-peptide glutathione to the C1 position of the antibi-
otic, cleaving the epoxide ring and rendering it ineffective as
an antibacterial drug [61]. FosA is a Mn (II)- and K+-depen-
dent glutathione transferase. Among glutathione transferase
(FosA type) enzymes found to be plasmid-borne are FosA3,
FosA4, FosA5 and FosC2 [80]. FosA3 is the most prevalent
gene variant, distributed mainly among both clinical and
non-clinical E. coli isolates from Asian countries (China,
South Korea and Japan) and, recently, in Europe [81–85].
FosA is encoded by clinically relevant Gram-negative species
and contributes to intrinsic fosfomycin resistance. Chromo-
somal fosA genes conferred high-level fosfomycin resistance
when expressed in E. coli, and deletion of chromosomal fosA
in Serratia marcescens eliminated fosfomycin resistance
[86]. However, other Gram-negative species, like E. coli,
exhibited lower susceptibility to fosfomycin [87]. For exam-
ple, clinical strains of K. pneumoniae producing KPC-type
carbapenemase have a MIC50/90 of 16/64 µgml
 1 [88].
FosB (the amino acid sequence is 48% identical to that of
FosA) is an Mg2+-dependent L-cysteine thiol transferase.
FosX is a Mn (II)-dependent fosfomycin-specific epoxide
hydrolase and is found in L. monocytogenes, Clostridium
botulinum and Brucella melitensis [5, 89]. In fact, FosB is
produced by Gram-positive bacteria but FosA and FosX
enzymes are produced by Gram-negative bacteria [45]. Nev-
ertheless, they differ in terms of chemical mechanism, using
different substrates to add chemical groups to the antibiotic.
An analysis of plasmid-encoded fosfomycin resistance in
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pathogenic bacteria showed a relatively low percentage of
fosA and fosB genes among fosfomycin-resistant strains.
Multidrug resistance plasmids encoding fosA3, fosC2, bla-
TEM–1b, blaCTX–M–65 and rmtB carry the genes conferring
resistance to fosfomycin, penicillins, cephalosporins and
aminoglycosides, respectively, emerging among ESBL E. coli
and K. pneumonia isolates in Asia (China, Japan and South
Korea) [5]. However, little is yet known about the molecular
mechanisms of fosfomycin resistance in clinical bacterial
isolates. Therefore, a more in-depth knowledge of the
molecular mechanisms involved in fosfomycin resistance in
clinical strains could improve the efficacy of fosfomycin in
the treatment of bacterial infections. Development of fosfo-
mycin resistance may also confer a biological cost, which
could be attributed to the loss of important cellular func-
tions (decreased growth rate in vitro and/or in vivo as well
as decreased virulence)[90]. Biological cost can often be
reduced by compensatory mutations, and such genetic com-
pensation has been described for several antibiotics and bac-
terial species both in vitro and in vivo[62].
PREVALENCE OF FOSFOMYCIN RESISTANCE
The history of fosfomycin resistance emergence goes back
to 1977, when resistant E. coli and Salmonella typhimurium
colonies became apparent in a zone of inhibition around
fosfomycin [91]. Since then, the prevalence of resistance has
varied among countries, as well as among bacterial species
found in individual countries. The mechanism of resistance
also plays an important role in the spread of resistance
within a region. To date, not all countries have reported
data on fosfomycin resistance; for certain countries, limited
data are available (Fig. 3). Moreover, it should be noted that
the results of fosfomycin susceptibility testing deserve care-
ful interpretation because, in routine testing, media are not
supplemented with glucose-6-phosphate, resulting in some
sensitive strains appearing resistant.
Asia
Studies demonstrate that the overall fosfomycin resistance
in China is higher than in other parts of the world in both
human and animal hosts, which could be attributed to the
mechanism of resistance. There is preliminary evidence that
fosA3 is the main mechanism responsible for fosfomycin
resistance in E. coli isolates in China [92]. Studies from
Hong Kong indicated that levels of human and animal hosts
carrying the fosA3 gene in E. coli isolates are 44 and 96%,
respectively [82, 93]. Although the overall rate of resistance
is less than for other antimicrobial agents, increasing resis-
tance is the main issue of consideration and concern. In a
study conducted on E. coli isolates obtained from 20 tertiary
Chinese hospitalsin 2009–2010, the rate of fosfomycin resis-
tance was 7.8% [94]; CAO et al. reported a 10% level of
resistance in urine-derived E. coli isolates in 2010–2014
[92]. This increase in rate could be explained by the fact
that high prevalence of the fosA3 gene is concurrent with
the high transferability of fosA3-harbouring plasmids,
accounting for further transmission of resistance [92].
The prevalence of bacterial resistance other than in E. coli
varies greatly among bacterial species. The resistance rate in
K. pneumoniae is higher, about 60.8% in KPC-producers
and 12.5% among ESBL-producers [95]. In addition, data
have shown that fosA3 was responsible for resistance in
more than 50% of cases [95]. As more than 71% of fosA3-
positive cases belonged to clonal group I, it could be inferred
that high-level resistance was likely due to clonal dissemina-
tion, indicating the significant impact of this clone in Chi-
nese hospitals [95]. On the other hand, the emergence of
fosA3 and blaKPC-2 on the same transposon in China is an
issue of concern in regard to multidrug-resistant Enterobac-
teriaceae [96]. Dissemination of such resistance by a single
mobilizable element threatens two classes of last-line anti-
microbials in this region [96]. Besides, a drastic increase in
resistance was observed in MRSA isolates. In 2010, 29.5%
of MRSA isolates were fosfomycin-resistant, reaching 70%
in 2014 [97]. Such an increase necessitates care in prescrib-
ing fosfomycin for S. aureus, particularly for MRSA infec-
tions in Shanghai hospitals.
The other issue is the widespread occurrence of fosfomycin
resistance among animals in China, which is considerably
higher than that of other countries. In a previous study,
10.2% of E. coli isolates obtained from domestic pets
showed resistance to fosfomycin, even though these had not
received fosfomycin treatment [84]. Remarkably, molecular
typing results showed that some strains isolated from pet
owners were identical to those from their animals [98]. This
finding tends to confirm the hypothesis that since pets are
in close contact with humans, the former can act as vectors
and accelerate further human-to-pet or pet-to-human fosA3
dissemination [98]. On the other hand, in addition to
E. coli, the fosA3 gene has been identified in Proteus mirabi-
lis, E. fergusonii and Citrobacter freundii isolates, implying
the broad host range of this gene in animals in China [98].
Another study investigated the prevalence of fosA3-medi-
ated resistance among E. coli isolates obtained from chick-
ens in China [99]. The results revealed a not insignificant
resistance rate (27.4%), suggesting widespread distribution
of fosA3 in chickens on Chinese farms [99].
On the other hand, plasmid-mediated resistance genes other
than fosA3 have proved to be a significant challenge regard-
ing the effectiveness of fosfomycin in China. The increase in
resistance conferred by fosB and fosB3 among vancomycin-
resistant Enterococci (VRE), particularly E. faecium, suggests
the prudent use of Fosfomycin treatment for VRE infections
as well as continuous monitoring of resistance, at least in
some areas of China [100, 101]. FosXCC-mediated resistance
in Campylobacter spp. and fosB-associated resistance in
MRSA isolates demonstrate the diversity of plasmid-
mediated resistance in China [97, 102].
Fosfomycin was approved by Japan in 1980; nevertheless,
the literature shows no significant concern about resistance
in this country. Despite the increasing prevalence of resis-
tance in some areas, only 3.6% of CTX-M-producing E. coli
isolated from Japanese clinical settings were recognized as
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resistant, in which fosA3 and fosC2 were resistance determi-
nants [103]. However, fosfomycin resistance has drawn
attention in bacterial species other than E. coli. Pseudomo-
nas aeruginosa and Shiga-like toxin-producing E. coli
obtained from clinical isolates showeded a high resistance
profile for fosfomycin [104, 105]. The most alarming find-
ing is a novel fosK gene in Acinetobacter soli HK001 that
resulted in high-level resistance (MIC>8000 µgml 1) [106].
Studies have clarified that healthy individuals and veterinary
settings also contribute in the distribution of fosfomycin
resistance, as well as clinical isolates, in Japan [83]. Sato
et al. demonstrated that 5.8 % of CTX-M-producing E. coli
from healthy individuals were fosfomycin resistant [83]. A
recent study investigated the fosfomycin susceptibility of
P. aeruginosa isolates collected from cats and dogs in pri-
mary veterinary hospitals [107]. According to this report,
3.5% of isolates displayed resistance to fosfomycin [107].
As mentioned previously, animals with a fosfomycin-resis-
tant profile can be involved in the horizontal dissemination
of resistance.
There are relatively few reports demonstrating the preva-
lence of resistance in Korea. In one study, resistance was
found in 4.2% of E. coli and 5.5 to 38.3% of K. pneumoniae
isolates, and both strains were ESBL-producers [81]. The
prevalence of fosA3 among E. coli isolates was higher than
for K. pneumoniae (62.5 vs 15.4%) [81, 108]. Based on this
finding, fosfomycin is apparently not an appropriate alter-
native treatment for UTIs related to ESBL-producing Klebsi-
ella spp. in Korea [108]. In another Korean study, the
susceptibility of 307 ciprofloxacin-resistant and/or ESBL-
producing E. coli isolates was evaluated [109]. Only one
isolate showed resistance to fosfomycin, suggesting the
desirable efficacy of the drug on ciprofloxacin-resistant E.
coli isolates [109].
Published data informing fosfomycin resistance in Iran is
limited; only a few studies provide some insight into the
resistance rate in this region. In more recent studies, resis-
tance was found in 1.1% of E. coli and 3.6% of Klebsiella
spp., but all P. mirabilis, Proteus vulgaris, C. freundii, E. fae-
calis and Klebsiella oxytoca isolates were fully susceptible
[110–112]. Notably, all Morganella morganii isolates were
100% resistant [110]. Mindful of the limited number of
studies, the available data show that the resistance rate in
Iran is lower than in other Asian countries.
Data from studies in Turkey show higher resistance rates
than in an adjacent country, Iran. Although the drug has
become available for clinical use only recently, the resistance
rate among E. coli isolates ranges from 0 to 15% in some
regions [113–115]. Moreover, K. pneumoniae isolates
showed more resistance, particularly ESBL-producing ones
(26.6%) [116]. In a 4-year study by Demir et al., 4.4 % of
Enterobacter spp. and 9.4% of Proteus spp. were resistant to
fosfomycin [116]. Remarkably, resistance rates were higher
in A. baumannii and Pseudomonas spp., 48.6 and 56%,
respectively [116]. Similar to the data from Iran, all M. mor-
ganii isolates were resistant. However, the drug was found
to be effective against Serratia and Citrobacter spp. and all
Fig. 3. The universal prevalence of fosfomycin resistance based on available data
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isolates were susceptible [116]. It should be noted that due
to limited numbers of some strains, these results should be
interpreted with caution [116].
A range of recent studies in Taiwan has provided evidence
that fosfomycin still remains the drug of choice in the treat-
ment of commonly encountered pathogens. The drug shows
superior activity against S. aureus, including most MRSA
strains, although resistant strains have been noted
(MIC>512mg l 1) [27]. In addition, it appears to have a
useful effect against both vancomycin-resistant and -
sensitive Enterococci [27]. The drug is found to be the most
active oral agent against MDR Enterobacteriaceae, with
94.5% susceptibility [117]. Studies indicate that fosfomycin
retains its activity against ESBL-producing E. coli isolates,
with a resistance range of 0 to 4.5% over the years [27, 118].
Besides, one study analysed decade-long data from a nation-
wide surveillance programme and reported a low increase in
the resistance spectrum of fosfomycin in E. coli from com-
munity settings [119]. Non-susceptibility to fosfomycin is
different in human and animal E. coli isolates, with relatively
high resistance in pig-derived isolates (22%) [120]. In con-
trast to E. coli, resistance in ESBL-producing K. pneumoniae
is higher in Taiwan than in other Asian countries [121].
ESBL-producing K. pneumoniae isolates have shown 27.8
and 57.6% resistance in southern and northern Taiwan,
respectively [118, 121]. Moreover, the molecular mechanism
responsible for fosfomycin resistance in Taiwan differs from
that in other Asian countries. In Taiwan, the main resis-
tance mechanism is amino acid variation in the GlpT and
UhpT transporters, regulatory genes (uhpA and pstI) and
modification of the target gene (murA), while, as mentioned
previously, fosA3 is the major factor in China, Japan and
Korea [121].
The susceptibility pattern of fosfomycin in Pakistan is rela-
tively similar to that in other parts of Asia. To date the drug
has provided significant results against ESBL-producing and
non-ESBL-producing E. coli, with respective non-suscepti-
bility rates of 0–15% [122–124]. Although resistance rates
are still low, the steep rise since 2005, particularly in pus iso-
lates, indicates an emerging threat [122]. The main concern
is Proteus spp. which is known to be the most resistant path-
ogen (67% non-susceptibility), followed by Acinetobacter
and K. pneumoniae with 50 and 40% resistance, respectively
[125–127]. Enterococcus spp. also have shown resistance, at
40% [128].
Due to a lack of published evidence in Afghanistan, Iraq,
Malaysia and United Arab Emirates, the exact prevalence of
resistance and associated molecular mechanisms remains
unclear. Although no single study can demonstrate the
microbial resistance rate of a country, it can help estimate
the ongoing situation. In Afghanistan, Tariq et al. reported
the fosfomycin susceptibility profile of blood culture isolates
as follows: 21.7% of Gram-negative bacilli were fosfomycin
resistant, as well as 27.2% of Gram-positive cocci [129]. In a
study from Iraq, fosfomycin resistance was also lower than
for other antimicrobial agents including cefepime,
cefotaxime and tetracycline in ESBL-producing E. coli iso-
lates (3.1 vs 100%) [130].
Based on the available data regarding uropathogens, fosfo-
mycin susceptibility is promising in Malaysia, presenting
only 1% resistance [131]. On the other hand, it seems that
among animals in Malaysia, fosfomycin resistance is of par-
ticular concern. The antibiotic resistance of bacterial species
in seafood animals could cause massive economic losses to
aquaculture operations. Moreover, resistance could be
transmitted directly to humans through the handling of sea-
food animals with a resistant profile. To prevent such an
occurrence, studies have been conducted to evaluate the sus-
ceptibility of related bacteria to a variety of antimicrobials.
As a result, fosfomycin resistance has been observed in Sal-
monella spp. obtained from chicken and in Vibrio alginolyti-
cus isolated from white-leg shrimps [132, 133].
Compared with other Asian reports, encouraging statistics
have been reported from United Arab Emirates. Although
only a single study was available, fosfomycin was reported
to be active against common ESBL-producing uropatho-
gens, among which 100% of isolates were susceptible [134].
Fosfomycin has been available in Thailand for many years,
but the resistance rate is rather low. It has been shown to be
an active antibiotic against ESBL-positive E. coli and
K. pneumoniae, as well as Enterococcus spp. [135, 136]. In a
5-year study evaluating the antimicrobial susceptibility of
S. aureus, Fosfomycin resistance was consistently low (7.7–
17%) [137], suggesting that the drug is an effective treat-
ment option. On the other hand, the high resistance rates in
A. baumannii (61.7 %) and P. aeruginosa (50%) imply the
inefficient activity of fosfomycin against these organisms in
Thailand [138].
India is considered a relatively fosfomycin-naïve population,
since the intravenous formulation of drug is not currently
marketed and the oral form has become available only
recently. Therefore, fosfomycin has emerged as an encour-
aging treatment option for Gram-positive isolates [139].
Overall, Staphylococcus, Enterococcus and Streptococcus spp.
are 99–100% susceptible, which is much higher compared
to the situation in countries such as China [140, 141]. In
addition, the drug has exhibited a good effect against E. coli
urine isolates, including ESBL-producing and non-ESBL-
producing,with 83–100% of isolates classified as susceptible
[141, 142]. The susceptibility of A. baumannii, P. aerugi-
nosa, K. pneumoniae and Enterobacter spp. is lower than in
E. coli, but still acceptable [139]. Nevertheless, one study
demonstrated that the cumulative resistance rate for fosfo-
mycin is 45.55% among AmpC-producing Gram-negative
bacilli [143]. The in vitro susceptibility of these bacteria to
fosfomycin suggests the latter as an efficient antimicrobial
option for UTI treatment, but not suitable for infections
associated with AmpC-producing isolates in India.
North and South America
Until recently, fosfomycin resistance has been reported
mainly from Asian countries, but resistance finally emerged
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in the Americas. Although fosfomycin was endorsed by the
Infectious Diseases Society of America (IDSA) in the USA
in 2010, only the oral formulation is available, and with lim-
ited experience of its use [144]. Reports from the USA show
variable efficacy for fosfomycin against K. pneumoniae. Two
studies from Ohio reported good efficacy against KPC-pro-
ducing K. pneumoniae, even the bacteria were colistin and/
or tigecyclin resistant (susceptibility 92 and 93%, respec-
tively) [39, 88]. On the other hand, studies from New York
and Boston reported higher rates of resistance: 46.4% in
Klebsiella spp. and 21 and 32% in ESBL-positive K. pneu-
moniae [145, 146]. As mentioned previously, Fosfomycin is
considered a promising treatment option for VRE, which is
consistent with reports from the USA. Against VRE, suscep-
tibility rates of 98.7 and 86% have been recorded [39, 147,
148].
In one study from Minnesota, among the 120 E. coli isolates
studied, 98–99% were susceptible to fosfomycin [149]. Con-
sistent with this, another study reported only 4% resistance
among E. coli isolates, indicating the excellent activity of fos-
fomycin against E. coli [146]. The data available from the
USA only discuss resistance prevalence, with the machan-
isms responsible remaining unclear. Only one report, from
Pennsylvania, demonstrated the emergence of the fosA3
gene, conferring a high level of resistance to E. coli in clinical
isolates [150]. The structural similarities of fosA3-carrying
plasmids introduce the idea that this multidrug resistance
plasmid has emerged in the USA through the importation of
food products or human travel [150].
In a study from Argentina, >94% of E. coli and K. pneumo-
niae isolates were susceptible to fosfomycin; however, the
development of resistance in P. mirabilis was higher, with
72% susceptibility [151]. In the same study, the in vitro
activity of fosfomycin against Staphylococcus spp. and Strep-
tococcus agalactiae was higher than in other countries, with
97.2% susceptibility [151].
In Mexico, the antimicrobial activity of ESBL-producing
E. coli and K. pneumoniae was assessed by Morfın-Otero
et al., suggesting that fosfomycin is an effective agent, with
96.9 and 94.4% susceptibility rates, respectively [152].
Studies of susceptibility in Canada demonstrate excellent
activity for fosfomycin against E. coli isolates. The in vitro
activity of fosfomycin was evaluated against 868 urinary
E. coli isolates as part of the Canadian national surveil-
lance study CANWARD. The drug demonstrated good
activity, with an overall 99.4% susceptibility rate [153].
Moreover, ESBL- and AmpC-producing E. coli isolates
remained highly susceptible, presenting 94–100% suscepti-
bility [153]. However, some studies have reported the
presence of other fosfomycin resistance determinants in
Canada. One study reported the discovery of fosA2-pro-
ducing Enterobacter cloacae by PCR amplification and
sequencing in aquatic samples taken from a salmon river
in western Canada [154], while another demonstrated fosB
in canine methicillin-resistant Staphylococcus pseudinter-
medius isolates [155].
The activity of fosfomycin in Brazil demonstrated results
similar to other countries on that continent. In general, fos-
fomycin proved to be effective against the majority of
E. coli, KPC-producing K. pneumoniae, S. marcescens and
VRE [156–158]. However, higher MICs were reported for
S. aureus, Stenotrophomonas maltophilia and A. baumannii
[156, 159].
Africa
The susceptibility of fosfomycin in Africa has seldom bee-
nassessed; for some countries data are very limited (Mada-
gascar, Senegal, Algeria, Morocco, Tunisia and Egypt) and
for others there are no available data. Therefore, a compre-
hensive decision on fosfomycin susceptibility for the whole
continent has not been reached. However, the available data
could help to elucidate the current situation. In African
countries generally, resistance among E. coli isolates can be
classified according to those having a higher resistance rate,
such as Egypt, and those with 0–3% resistance, including
South Africa and Madagascar [160–162]. However, the
overall resistance to fosfomycin in Africa is much lower
than that observed in certain Asian countries. In addition, it
was introduced as the antibiotic most active against E. coli
isolates obtained from patients with UTIs [161]. With
regard to Klebsiella spp. isolates, the overall resistance is
higher than for E. coli, presenting up to 36% in ESBL-
producing Klebsiella from Egypt and up to 12.9% resistance
in other countries [163, 164]. A study from South Africa
reported the emergence of K. pneumoniae and Enterobacter
cloacae co-harbouring NDM-1 and KPC-2 enzymes [165].
Susceptibility testing revealed that fosfomycin and colistin
were the only active agents, highlighting the significance of
novel treatment options [165].
Europe
Studies have found low rates of fosfomycin resistance for all
European countries, despite many years of use. Recent Ger-
man data on antimicrobial fosfomycin susceptibility dem-
onstrate its high in vitro efficac. A recent multi-centre study
points to low levels of resistance (no more than 1.2%)
among E. coli isolates [166], although 4.5% resistance has
also been reported [167]. Other German studies show sus-
ceptibility in a considerable proportion of ESBL-producing
E. coli, P. mirabilis, VRE and even carbapenemase-produc-
ing Enterobacteriaceae against fosfomycin [167–169].
French results from the international ARESC (Antimicro-
bial Resistance Epidemiological Survey on Cystitis) study
reported high susceptibility of E. coli isolates to fosfomycin
[170]. Moreover, other French studies show that fosfomycin
remains active against ESBL-producing E. coli and coagu-
lase-negative Staphylococci, but less active against K. pneu-
moniae [171, 172]. In Spain, fosfomycin resistance in E. coli
shows some variation over time. Despite relatively low resis-
tance levels, two multi-centre studies describe a large
increase in resistance since 2003, in both ESBL-producing
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and non-ESBL-producing E. coli [173, 174]. It is assumed
that the increased rate in Spain is mainly due to elevated
administration of fosfomycin, alongside the acquisition of
resistance by CTX-M-15-producing E. coli isolates [174].
Although lower rates were reported for E. coli, resistance in
ESBL-positive K. pneumoniae is higher (54% nonsuscepti-
bility), similar to findings from Taiwan [175]. Data from an
ECO.SENS study, as well as from other studies, clearly show
the high efficacy of fosfomycin in Austria, Portugal and the
Netherlands [176–178], even against carbapenemase- and
ESBL-producers [179].
UK data confirm fosfomycin as a useful therapeutic option
for multidrug-resistant P. aeruginosa in CF patients, as well
as in UTIs caused by multidrug-resistant E. coli, including
ESBL-producers [180, 181]. However, higher resistance lev-
els (39.5 %) among carbapenem-resistant Enterobacteriaceae
query the impact of fosfomycin against these pathogens
[182]. The susceptibility pattern of fosfomycin has been
widely studied in Greece. Data from three large Greek uni-
versity hospitals, consistent with other studies, show fosfo-
mycin activity against a substantial proportion of both
Gram-negative and-positive pathogens. The available data
demonstrate a fully susceptible profile for E. coli, particu-
larly MDR and XDR strains, Salmonella spp. and S. aureus,
including MRSA [51, 182, 183]. Moreover, surprising sus-
ceptibility rates have been reported in P. mirabilis and
S. marcescens, with >96 and 83% susceptibility, respectively
[184]. The high susceptibility of carbapenemase- and ESBL-
positive K. pneumoniae (90.5%) indicates that fosfomycin is
a promising treatment option for Enterobacteriaceae in
Greece, regardless of multidrug resistance [185]. In contrast,
the drug appears to be inactive against A. baumannii, since
in one study all 73 A. baumannii isolates were resistant [51]
and in another study only 9% susceptibility was reported
[184].
In Switzerland and Italy, fosfomycin has been found to be
the most active agent against ESBL-producing E. coli, pre-
senting 100 and 98% efficacy, respectively [186–188]. Fosfo-
mycin susceptibility rates in Sweden are high in E. coli,
particularly in ESBL-producing strains (97–99%), support-
ing the replacement of antibiotics exhibiting reduced activ-
ity by fosfomycin [189, 190].
CONCLUSION
The available data show that fosfomycin has a high level of
antimicrobial activity against a broad spectrum of Gram-
positive and -negative bacteria. Although clinical evidence is
still limited, fosfomycin may represent a valuable treatment
option for community-acquired UTIs caused by these
pathogens. Oral fosfomycin is used for the treatment of
UTIs, mainly those caused by E. coli and E. faecalis. The
intravenous administration of fosfomycin, which is associ-
ated with a low incidence of adverse effects, has been uti-
lized in combination with other antibiotics for the
treatment of MDR Gram-positive and -negative bacteria. In
particular, data regarding the use of fosfomycin use for the
treatment of such infections are awaited to further delineate
issues concerning the optimal clinical use of this antimicro-
bial agent.
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